



基质细胞衍生因子1对骨髓间充质干细胞的趋化作用

孙立影, 韩明子

■背景资料

近年来, 随着干细胞研究热潮的不断兴起, 骨髓间充质干细胞越来越受到重视, 他具有可塑性强、取材方便以及容易培养等优点, 但也存在很多问题尚待解决, 核心问题之一就是移植细胞在宿主体内的迁移和转化情况。趋化因子SDF-1具有广泛的生物活性, 最初认为对造血干细胞的归巢有重要作用, 近年来研究发现其对骨髓间充质干细胞也有趋化作用。

孙立影, 韩明子, 哈尔滨医科大学附属第二医院消化科 黑龙江省哈尔滨市 150086

作者贡献分布: 孙立影, 韩明子对本文所作贡献均等; 此课题设计由孙立影及韩明子共同完成; 经费由韩明子提供; 实验操作及论文撰写由孙立影完成。
通讯作者: 韩明子, 150086, 黑龙江省哈尔滨市, 哈尔滨医科大学附属第二医院消化科. hanmingzi@medmail.com.cn
电话: 0451-86605143

收稿日期: 2007-09-10 修回日期: 2008-03-01

Huaren Xiaohua Zazhi 2008; 16(9): 992-997

摘要

骨髓干细胞主要由造血干细胞和间充质干细胞组成, 其中骨髓间充质干细胞除具有自我更新和多向分化的潜能外, 更具有很强的可塑性, 在一定的诱导条件下能向多细胞分化, 且其相对容易获得, 成为近年来研究的热点。许多体内外试验证实, 细胞因子可以影响移植细胞的微环境, 进而影响骨髓干细胞的动员、迁移及分化。基质细胞衍生因子1是一类对免疫细胞有趋化作用的小分子蛋白, 属于CXC趋化因子之一, 具有广泛的生物学活性, 对骨髓干细胞亦有趋化作用, 现就SDF-1对骨髓间充质干细胞的趋化作用作一综述。

关键词: 基质细胞衍生因子1; 骨髓间充质干细胞; 趋化作用

孙立影, 韩明子. 基质细胞衍生因子1对骨髓间充质干细胞的趋化作用. 世界华人消化杂志 2008; 16(9): 992-997
<http://www.wjgnet.com/1009-3079/16/992.asp>

Chemotaxis of stromal cell-derived factor-1 on bone marrow mesenchymal stem cells

Li-Ying Sun, Ming-Zi Han

Li-Ying Sun, Ming-Zi Han, Department of Gastroenterology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, Heilongjiang Province, China
Correspondence to: Ming-Zi Han, Department of Gastroenterology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, Heilongjiang Province, China. hanmingzi@medmail.com.cn

Received: 2007-09-10 Revised: 2008-03-01

Abstract

Bone marrow stem cells (BMC) mainly include hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC). MSC not only have the potential capability of self-renewal and multi-directional differentiation, but also have a higher plasticity to differentiate into a variety of cells under the specific conditions. In addition, MSC can be easily obtained, and have been extensively studied in recent years. Many studies *in vivo* and *in vitro* have confirmed that some cytokines can influence the microenvironment of transplanted cells, resulting in the mobilization, migration and differentiation of BMC. Stromal cell-derived factor-1 (SDF-1) is a CXC-type chemokine with a wide biological activity, and it also has chemotaxis effect on BMC, which is reviewed in this article.

Key Words: Stromal cell-derived factor-1; Bone mesenchymal stem cell; Chemotaxis

Sun LY, Han MZ. Chemotaxis of stromal cell-derived factor-1 on bone marrow mesenchymal stem cells. Shijie

0 引言

骨髓中主要包括两种多能干细胞, 即造血干细胞(hematopoietic stem cells, HSC)和间充质干细胞(mesenchymal stem cells, MSC)。其中, MSC是与HSC截然不同的一类干细胞, 除具有自我更新和多向分化的潜能外, 更具有很强的可塑性, 在一定的诱导条件下能分化为多种细胞, 且取材方便、培养容易、增殖较快。近年来, 随着对干细胞的研究和应用热潮的不断兴起, 骨髓间充质干细胞越发受到重视。众多体内外实验表明细胞因子可以影响干细胞移植的微环境^[1-6], 进而影响骨髓间充质干细胞的动员、迁移及分化。基质细胞衍生因子1(stromal cell-derived factor-1, SDF-1)是属于CXC趋化因子之一, 具有广泛的生物学活性, 在造血、神经、心血管系统发育以及人类免疫缺陷病毒(human immuno deficiency virus, HIV)感染中发挥重要作用。本文就SDF-1对骨髓间充质干细胞的趋化作用作一综述。

■同行评议者
余宏宇, 教授, 中国人民解放军第二军医大学第二附属医院长征医院病理科; 张凤春, 教授, 上海交通大学医学院附属仁济医院肿瘤中心主任

1 SDF-1及其受体

1.1 SDF-1 趋化因子是一类对免疫细胞有趋化作用的小分子蛋白质, M_r 为8000-14 000, 可分为CXC、CC、C和CX3C这4个家族. Nagasawa *et al*^[7]首先在小鼠骨髓基质细胞分泌的细胞因子中发现了SDF-1, 它包括SDF-1 α 和 SDF-1 β , 两者区别在于前者比后者少4个氨基酸^[8]. 根据其氨基酸序列将其归类于趋化因子CXC亚家族, 命名为CXCL12. 现已知SDF-1在大脑、心、肺、肝、骨骼肌、胸腺、脾和肾等多种组织中都有表达^[9]. SDF-1种群间保守性极强, 人源性SDF-1和鼠源性SDF-1同源性高达99%, 人源SDF-1基因定位已经明确, 其基因位于10号染色体长臂^[10]. SDF-1其受体CXCR4(又称LESTR), 是一个有7个跨膜结构域的G蛋白耦联的受体, 在白细胞、CD34 $^+$ 造血干细胞及CD34 $^+$ 祖细胞表面都有广泛表达^[11]. 最初认为CXCR4是SDF-1惟一的受体^[12], 并将SDF-1与CXCR4特异性结合称为SDF-1/CXCR4轴. 近几年研究发现SDF-1的另一受体CXCR7, 曾称为孤儿受体RDC1^[13], 它主要表达于许多肿瘤细胞系、活化的内皮细胞及胎肝细胞, 大多数正常细胞表面不表达, 但内部能检测到丰富的CXCR7^[14].

1.2 SDF-1与其受体的相互作用 SDF-1具有广泛的生物学活性, 在维持造血、神经及心血管系统的发育、干细胞运动、血管形成、凋亡以及肿瘤发生、HIV感染中发挥重要的生物学作用, SDF-1与其受体结合, 是SDF-1发挥其生物学效应的基础. 目前SDF-1和CXCR4的结合动力学尚存争论, 大部分研究支持SDF-1和CXCR4相互作用的双位点模型(two site model), 即CXCR4 N端首先与SDF-1 N端第12-17位氨基酸(R-F-F-E-S-H)结合, 启动SDF-1和CXCR4构象的变化, SDF-1 N端处于无序状态的第1-11位氨基酸(K-P-V-S-L-S-Y-R-CPC-)形成特定构象, 并与CXCR4螺旋区的凹槽结合, 从而诱导CXCR4跨膜螺旋区的构象变化, G蛋白复合物中的G α 亚基和G $\beta\gamma$ 亚基解离, G $\beta\gamma$ 亚基结合和活化磷脂酶C、磷脂酰肌醇-3激酶和腺苷环化酶等, 引起一系列细胞内信号传递, 使细胞活化, 产生趋化运动, 细胞定向迁移至趋化因子浓度较高的组织器官部位^[15]. 而SDF-1与CXCR7的作用机制尚不明确, 有研究认为CXCR7通过CXCR4对SDF-1进行信号转导^[16], 也有人认为CXCR7和CXCR4相对独立的作用于SDF-1^[17-18].

2 骨髓间充质干细胞

2.1 生物学特性 MSC又称骨髓基质干细胞(bone marrow stromal cells), 是一种存在于骨髓中的非造血干细胞, 具有自我更新、分化增殖和多向分化潜能, 在特定的微环境和适宜的细胞因子作用下可分化为中胚层和神经外胚层组织细胞, 如成骨细胞、软骨细胞、脂肪细胞、内皮细胞、肌肉细胞、心肌细胞和神经细胞等^[19-23]. MSC在无诱导物的培养液中生长成纺锤状成纤维细胞样, 并表达SH2、SH3、CD29、CD44、CD27、CD90、CD105、CD106、CD166、CD120a和CD124^[24-25], 而缺乏造血干细胞表面的CD34和白细胞表面的CD45标志.

2.2 免疫学特性 近年来不少研究发现将同种异体的或异种的MSC通过局部直接注射、蛛网膜下腔植入、动脉、静脉移植等途径植入后, 在受者体内并未发生免疫排斥, 表明MSC有特殊的免疫学特征: (1)MSC表达组织相容性复合物I而不表达组织相容性复合物II, 且缺乏共刺激因子的表达, 因此免疫原性较弱^[26-27]. (2)MSC能直接或间接抑制T细胞的功能, 同时对CD4 $^+$ 和CD8 $^+$ 淋巴细胞也有抑制作用^[28]. (3)MSC具有免疫调节的功能^[29].

3 SDF-1对MSC的趋化作用

3.1 趋化作用 1997年, Aiuti *et al*^[30]首次发现SDF-1是CD34 $^+$ 造血干细胞的趋化因子, 提出CD34 $^+$ 细胞可能沿SDF-1浓度梯度向骨髓迁移实现归巢. 随后, 大量的研究不断证实SDF-1在骨髓干细胞的细胞迁移中起重要作用, 并且发现来源于骨髓、脐血动员的外周血中的CD34 $^+$ 造血干/祖细胞表面表达其相应受体CXCR4, 而SDF-1能特异地对CXCR4产生趋化作用^[12]. 研究证实, MSC可表达CXCR4^[31], 但有人认为MSC只有少部分表达CXCR4. Wynn *et al*^[32]通过流式细胞术检测显示活化的CXCR4仅表达于小部分MSC亚型的表面, 但经过Triton X-100处理后, MSC的CXCR4表达大量增加, 认为MSC内部有丰富的CXCR4表达, 应用抗体阻断CXCR4后发现MSC在循环中向骨髓的归巢行为大大减弱. 而在体外实验^[33-34]中通过对MSC转染CXCR4基因, 增加MSC表面CXCR4的表达, 大大增加了SDF-1对MSC的趋化作用, 进而证实了SDF-1通过受体CXCR4对MSC产生趋化作用, 而SDF-1是否通过另一受体CXCR7作用于MSC尚不清楚.

SDF-1浓度梯度在MSC的迁移中发挥着重

■研发前沿

骨髓间充质干细胞可以向多细胞分化已成定论, 如何更有效的诱导分化及其分化机制尚不清楚. 趋化因子SDF-1可以通过其受体作用于骨髓间充质干细胞迁移归巢, 但如何更有效的应用SDF-1也不明确.

■ 相关报道

研究表明MSC不仅在神经、心血管系统的损伤修复以及器官移植中有较大的潜在价值，并且证实MSC可以转化为肝干细胞、类肝样细胞以及肝细胞，在一些细胞因子的诱导下可以促进MSC向肝脏迁移并向肝细胞分化。

要作用，而当SDF-1或CXCR4被阻断后，这种定向迁移也就被阻断^[35]。除了运用CXCR4及SDF-1抗体，运用各种途径提高骨髓SDF-1的浓度也可以达到促进移植细胞归巢到骨髓的目的。降低骨髓内SDF-1的浓度^[36-37]或提高骨髓外SDF-1的浓度^[38]，所产生的骨髓内、外SDF-1浓度梯度都可以促进骨髓干细胞的动员。Ji *et al*^[31]当把SDF-1 α 注射到动物颅内神经损伤部位后，通过局部提高SDF-1可以趋化MSC到达颅内，且注射SDF-1 α 部位可见分化的神经细胞。庄瑜 *et al*^[39]在大鼠心肌梗区域给与注射SDF-1、SDF-1抗体及设置盐水对照组，经尾静脉注射MSC，发现注射SDF-1组MSC较其他组明显增多，抗SDF-1组最少，可见SDF-1对MSC的趋化作用与其浓度呈正相关。但超过一定浓度时反而减弱趋化作用，丁鹏 *et al*^[40]通过Boyden小室法证实趋化因子SDF-1(5、50、500 μ g/L)体外可以趋化MSC，并且发现SDF-1浓度为50 μ g/L时趋化作用达到高峰，同时观察到抗SDF-1多克隆抗体可对抗SDF-1的趋化迁移作用，从侧面证实了SDF-1对MSC体外迁移的特异性。

然而SDF-1对MSC的趋化作用还需要组织器官存在损伤区域。Abbott *et al*^[41]发现无心肌梗死小鼠中无论有无SDF-1的表达，都仅有少量的骨髓干细胞迁徙到心肌中，但与心肌梗死组有明显差异；提示骨髓干细胞归巢不只是需要SDF-1的趋化作用，心肌梗死区域的存在本身就具有重要作用。还有研究发现SDF-1在损伤器官的表达中存在一个时间窗，Ma *et al*^[42]在大鼠急性心肌梗死模型中发现梗死后d 1梗死区SDF-1的含量显著升高并达到峰值，随后逐渐下降，并且发现利用SDF-1的效应进行有效的治疗，需把握住这个时间窗或者重建梗死区SDF-1的表达^[43]。

3.2 作用机制 目前SDF-1趋化MSC的机制尚不明确，较多研究表明，SDF-1通过其受体激活细胞内多个信号传导途径，并受多种调节因子影响。SDF-1与CXCR4结合后通过第二信使如NO, IP3, Ca^{2+} 等引起的细胞内一系列相关激酶的磷酸化，某些核转录因子如NF κ B, ELK-1等磷酸化使核内的某些核蛋白磷酸化，改变骨髓干细胞的遗传信息，产生肌动蛋白快速、短暂聚合等生物效应^[44]。这可能是SDF-1诱导细胞迁移的分子基础。蛋白激酶B、细胞外信号调节蛋白-2和JAK/STAT家族成员JAK2也参与了SDF-1-CXCR4信号传导途径^[45]。

另外SDF-1能够充当骨髓干细胞定向迁移

的化学引诱物^[35,46]，同时他也可以增强骨髓干细胞的运动能力^[47]，这可能是SDF-1趋化MSC的机制。骨髓干细胞到达靶器官后，首先要黏附到血管内皮上，SDF-1能够促进细胞黏附于纤维蛋白原、纤维连接蛋白、间质和内皮细胞^[48-50]，而这种促进作用主要通过激活靶细胞表面的各种黏附分子，如淋巴细胞功能相关抗原-1(LFA-1)、晚期活原-4(VLA-4)和晚期活化抗原-5(VLA-5)等来实现^[49]。黏附到血管内皮的细胞随后要穿过血管壁从而进入靶器官，在SDF-1的作用下，可以分泌更多的基质金属蛋白酶-9(MMP-9)、一氧化氮和某些促进血管生长的因子，如血管内皮细胞生长因子(VEGF)^[51-52]，这些因子和酶都参与辅助细胞穿过血管壁的基底膜到达靶器官。

SDF-1还可能通过一些间接的途径趋化MSC，如促进其他生长因子分泌等。Mbemba *et al*^[53]发现，SDF-1具有聚糖和葡糖胺聚糖特性，能增加整合素ICAM-1和VCAM-1等多对受/配体间相互作用。其他细胞因子如SCF、HGF、IGF-1等，在干细胞动员、迁移中的作用也与SDF-1相关。SCF可以通过增加CXCR4的表达而增强SDF-1引起干细胞迁移^[46]。HGF可以SDF-1可以促进MSC向受损器官迁移^[54]。IGF-1可以增加CXCR4在MSC中的表达，并且促进MSC向SDF-1迁移的反应能力^[55]。

总之，随着干细胞领域基础研究的迅速进展，各种来源的干细胞已经广泛应用到各器官疾病治疗的基础研究和早期临床实验中。以往的研究表明MSC不仅在神经、心血管系统的损伤修复以及器官移植中有较大的潜在价值^[56-60]，并且证实MSC可以转化为肝干细胞、类肝样细胞以及肝细胞^[61-63]，在一些细胞因子的诱导下可以促进MSC向肝脏迁移并向肝细胞分化^[64]，这为肝脏疾病的细胞治疗^[65-67]提供了一条新方法。近年来国内外对晚期严重肝病的细胞治疗是将供体肝细胞通过介入通道输入体内或将其用于生物人工肝的细胞成分，但由于肝细胞来源有限，体外增殖困难且易丧失活性、永生化困难并有癌变危险，一直难以推广，MSC取材方便，体外扩增快速，且适合于自体移植，具有对病灶的趋化特性，是良好的转基因治疗的靶细胞。能否通过SDF-1来调控MSC向靶组织的迁移分化，有望为今后的研究提供新的思路。有研究认为SDF-1与肿瘤的发生有关^[68-69]，对于如何更有效的应用SDF-1、SDF-1应用的安全性及MSC的调控机制仍有待于进一步的研究。

4 参考文献

- 1 Kollet O, Shvitiel S, Chen YQ, Suriawinata J, Thung SN, Dabeva MD, Kahn J, Spiegel A, Dar A, Samira S, Goichberg P, Kalinkovich A, Arenzana-Seisdedos F, Nagler A, Hardan I, Revel M, Shafritz DA, Lapidot T. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. *J Clin Invest* 2003; 112: 160-169
- 2 Zhang GQ, Fang CH, Chi DZ. Hepatocyte growth factor induces differentiation of adult rat mesenchymal stem cells into a hepatocyte lineage in vitro. *Zhonghua Wai Ke Za Zhi* 2005; 43: 716-720
- 3 Kang XQ, Zang WJ, Bao LJ, Li DL, Song TS, Xu XL, Yu XJ. Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes. *World J Gastroenterol* 2005; 11: 7461-7465
- 4 Inderbitzin D, Avital I, Keogh A, Beldi G, Quarta M, Gloor B, Candinas D. Interleukin-3 induces hepatocyte-specific metabolic activity in bone marrow-derived liver stem cells. *J Gastrointest Surg* 2005; 9: 69-74
- 5 Stewart AA, Byron CR, Pondenis H, Stewart MC. Effect of fibroblast growth factor-2 on equine mesenchymal stem cell monolayer expansion and chondrogenesis. *Am J Vet Res* 2007; 68: 941-945
- 6 Maegawa N, Kawamura K, Hirose M, Yajima H, Takakura Y, Ohgushi H. Enhancement of osteoblastic differentiation of mesenchymal stromal cells cultured by selective combination of bone morphogenetic protein-2 (BMP-2) and fibroblast growth factor-2 (FGF-2). *J Tissue Eng Regen Med* 2007; 1: 306-313
- 7 Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. *Proc Natl Acad Sci U S A* 1994; 91: 2305-2309
- 8 Psenák O. Stromal cell-derived factor 1 (SDF-1). Its structure and function. *Cas Lek Cesk* 2001; 140: 355-363
- 9 Horuk R. Chemokines beyond inflammation. *Nature* 1998; 393: 524-525
- 10 Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, Honjo T. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. *Genomics* 1995; 28: 495-500
- 11 Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* 1996; 272: 872-877
- 12 Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* 1996; 382: 829-833
- 13 Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J Biol Chem* 2005; 280: 35760-35766
- 14 Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med* 2006; 203: 2201-2213
- 15 Dekker LV, Segal AW. Perspectives: signal transduction. Signals to move cells. *Science* 2000; 287: 982-983, 985
- 16 Sierra F, Biben C, Martínez-Muñoz L, Mellado M, Ransohoff RM, Li M, Woehl B, Leung H, Groom J, Batten M, Harvey RP, Martínez-A C, Mackay CR, Mackay F. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. *Proc Natl Acad Sci U S A* 2007; 104: 14759-14764
- 17 Damblay-Chaudière C, Cubedo N, Ghysen A. Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. *BMC Dev Biol* 2007; 7: 23
- 18 Valentin G, Haas P, Gilmour D. The chemokine SDF1a coordinates tissue migration through the spatially restricted activation of Cxcr7 and Cxcr4b. *Curr Biol* 2007; 17: 1026-1031
- 19 Salaszyk RM, Williams WA, Boskey A, Batorsky A, Plopper GE. Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells. *J Biomed Biotechnol* 2004; 2004: 24-34
- 20 Cui JH, Park SR, Park K, Choi BH, Min BH. Preconditioning of mesenchymal stem cells with low-intensity ultrasound for cartilage formation in vivo. *Tissue Eng* 2007; 13: 351-360
- 21 Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. *Eur J Cardiothorac Surg* 2006; 30: 353-361
- 22 Wislet-Gendebien S, Hans G, Leprince P, Rigo JM, Moonen G, Rogister B. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. *Stem Cells* 2005; 23: 392-402
- 23 Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. *Stem Cells* 2006; 24: 1054-1064
- 24 牛丽丽, 裴雪涛. 骨髓间充质干细胞在心血管疾病治疗中的应用. 中华内科杂志 2003; 42: 208-210
- 25 赵智刚, 邹萍. 骨髓间充质干细胞的研究进展及其应用前景. 临床内科杂志 2006; 23: 588-590
- 26 Bjorklund LM, Sánchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. *Proc Natl Acad Sci U S A* 2002; 99: 2344-2349
- 27 Saito T, Kuang JQ, Bittira B, Al-Khalidi A, Chiu RC. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. *Ann Thorac Surg* 2002; 74: 19-24; discussion 24
- 28 Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, Koç ON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. *Bone Marrow Transplant* 2004; 33: 597-604
- 29 Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005; 105: 1815-1822
- 30 Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic

■应用要点

MSC取材方便, 体外扩增快速, 适合于自体移植, 且具有对病灶的趋化特性, 是良好的转基因治疗的靶细胞, 鉴于其在神经、心血管系统以及肝脏的损伤修复中的潜在价值, SDF-1有望为肝脏疾病的细胞治疗提供了一条新方法。

■同行评价

本文结构清晰，条理清楚，具有一定科学性和可读性，是一篇较好的综述。

- progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. *J Exp Med* 1997; 185: 111-120
- 31 Ji JF, He BP, Dheen ST, Tay SS. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. *Stem Cells* 2004; 22: 415-427
- 32 Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. *Blood* 2004; 104: 2643-2645
- 33 Bhakta S, Hong P, Koc O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. *Cardiovasc Revasc Med* 2006; 7: 19-24
- 34 张志坚, 张佳林, 陈东平, 苏东辉, 刘春风. 基质细胞衍生因子-1对间质干细胞迁移的影响. 中国临床神经科学 2006; 14: 571-576
- 35 Ratajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowski Z, Peiper S, Janowska-Wieczorek A. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. *Stem Cells* 2003; 21: 363-371
- 36 Petit I, Szypner-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. *Nat Immunol* 2002; 3: 687-694
- 37 Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. *Leukemia* 2002; 16: 1992-2003
- 38 Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR, Quitoriano MS, Crystal RG, Rafii S, Moore MA. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. *Blood* 2001; 97: 3354-3360
- 39 庄瑜, 陈鑫, 石开虎, 徐明. 基质细胞衍生因子1在骨髓间质干细胞归巢到急性梗死心肌中的作用. 江苏医药 2007; 33: 579-582
- 40 丁鹏, 冯忠堂, 杨智勇, 王进昆, 李向新, 王伟民, 薛黎萍, 林荣安. 趋化因子SDF-1体外趋化骨髓基质细胞迁移的实验研究. 中华神经医学杂志 2007; 6: 225-227
- 41 Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. *Circulation* 2004; 110: 3300-3305
- 42 Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L, Wang K, Zou Y. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. *Basic Res Cardiol* 2005; 100: 217-223
- 43 Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. *Lancet* 2003; 362: 697-703
- 44 Wang JF, Park IW, Groopman JE. Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. *Blood* 2000; 95: 2505-2513
- 45 Tilton B, Ho L, Oberlin E, Loetscher P, Baleux F, Clark-Lewis I, Thelen M. Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes. *J Exp Med* 2000; 192: 313-324
- 46 Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 1999; 283: 845-848
- 47 Reca R, Mastellos D, Majka M, Marquez L, Ratajczak J, Franchini S, Glodek A, Honczarenko M, Spruce LA, Janowska-Wieczorek A, Lambris JD, Ratajczak MZ. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. *Blood* 2003; 101: 3784-3793
- 48 Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. *Circulation* 2003; 107: 1322-1328
- 49 Peled A, Kollet O, Ponomaryov T, Petit I, Franitzka S, Grabovsky V, Slav MM, Nagler A, Lider O, Alon R, Zipori D, Lapidot T. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. *Blood* 2000; 95: 3289-3296
- 50 Majka M, Janowska-Wieczorek A, Ratajczak J, Kowalska MA, Vilaira G, Pan ZK, Honczarenko M, Marquez LA, Poncz M, Ratajczak MZ. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. *Blood* 2000; 96: 4142-4151
- 51 Janowska-Wieczorek A, Marquez LA, Dobrowsky A, Ratajczak MZ, Cabuhat ML. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. *Exp Hematol* 2000; 28: 1274-1285
- 52 Kijowski J, Baj-Krzyworzeka M, Majka M, Reca R, Marquez LA, Christofidou-Solomidou M, Janowska-Wieczorek A, Ratajczak MZ. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. *Stem Cells* 2001; 19: 453-466
- 53 Mbomba E, Gluckman JC, Gattegno L. Glycan and glycosaminoglycan binding properties of stromal cell-derived factor (SDF)-1alpha. *Glycobiology* 2000; 10: 21-29
- 54 Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A. Migration of bone marrow

- and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. *Stem Cells* 2006; 24: 1254-1264
- 55 Li Y, Yu X, Lin S, Li X, Zhang S, Song YH. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. *Biochem Biophys Res Commun* 2007; 356: 780-784
- 56 Ohnishi S, Nagaya N. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure. *Am J Nephrol* 2007; 27: 301-307
- 57 Ohnishi S, Ohgushi H, Kitamura S, Nagaya N. Mesenchymal stem cells for the treatment of heart failure. *Int J Hematol* 2007; 86: 17-21
- 58 Dezawa M. Specific induction of neurons and Schwann cells from bone marrow stromal cells and application to neurodegenerative diseases. *No Shinkei Geka* 2005; 33: 645-649
- 59 Zhou B, Han ZC, Poon MC, Pu W. Mesenchymal stem/stromal cells (MSC) transfected with stromal derived factor 1 (SDF-1) for therapeutic neovascularization: enhancement of cell recruitment and entrapment. *Med Hypotheses* 2007; 68: 1268-1271
- 60 Ringdén O, Uzunel M, Rasmussen I, Remberger M, Sundberg B, Lönnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation* 2006; 81: 1390-1397
- 61 Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. *J Clin Invest* 2002; 109: 1291-1302
- 62 Li W, Liu SN, Luo DD, Zhao L, Zeng LL, Zhang SL, Li SL. Differentiation of hepatocytoid cell induced from whole-bone-marrow method isolated rat myeloid mesenchymal stem cells. *World J Gastroenterol* 2006; 12: 4866-4869
- 63 Oh SH, Witek RP, Bae SH, Zheng D, Jung Y, Piscaglia AC, Petersen BE. Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. *Gastroenterology* 2007; 132: 1077-1087
- 64 Lange C, Bruns H, Kluth D, Zander AR, Fiegel HC. Hepatocytic differentiation of mesenchymal stem cells in cocultures with fetal liver cells. *World J Gastroenterol* 2006; 12: 2394-2397
- 65 Shi M, Li J, Liao L, Chen B, Li B, Chen L, Jia H, Zhao RC. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. *Haematologica* 2007; 92: 897-904
- 66 Popp FC, Piso P, Schlitt HJ, Dahlke MH. Therapeutic potential of bone marrow stem cells for liver diseases. *Curr Stem Cell Res Ther* 2006; 1: 411-418
- 67 Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW, Yarmush ML. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. *PLoS ONE* 2007; 2: e941
- 68 Peng SB, Peek V, Zhai Y, Paul DC, Lou Q, Xia X, Eessalu T, Kohn W, Tang S. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epithelial carcinoma cells. *Mol Cancer Res* 2005; 3: 227-236
- 69 Sutton A, Friand V, Brûlé-Donneger S, Chaigneau T, Zioli M, Sainte-Catherine O, Poiré A, Saffar L, Kraemer M, Vassy J, Nahon P, Salzmann JL, Gattegno L, Charnaux N. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. *Mol Cancer Res* 2007; 5: 21-33

编辑 潘伯荣 电编 何基才

ISSN 1009-3079 CN 14-1260/R 2008年版权归世界华人消化杂志

• 消息 •

世界华人消化杂志作者署名要求

本刊讯 本刊论文署名作者不宜过多,一般不超过8人,主要应限于参加研究工作并能解答文章有关问题、能对文稿内容负责者,对研究工作有贡献的其他人可放入致谢中。作者署名的次序按贡献大小排列,多作者时姓名间用逗号,如是单名,则在姓与名之间空1格(正文和参考文献中不空格)。《世界华人消化杂志》要求所有署名人写清楚自己对文章的贡献。第一方面是直接参与,包括:(1)酝酿和设计实验;(2)采集数据;(3)分析/解释数据。第二方面是文章撰写,包括:(1)起草文章;(2)对文章的知识性内容作批评性审阅。第三方面是工作支持,包括:(1)统计分析;(2)获取研究经费;(3)行政、技术或材料支持;(4)指导;(5)支持性贡献。每个人必须在第一至第三方面至少具备一条,才能成为文章的署名作者。《世界华人消化杂志》不设置共同第一作者和共同通信作者。(常务副总编辑:张海宁 2008-03-28)